CompletedPhase 1NCT02962167
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Sabine Mueller, MD, PhD, MAS, MD, PhDUniversity of California, San Francisco
- Intervention
- Modified Measles Virus(biological)
- Enrollment
- 34 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2017 – 2023
Study locations (8)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Seattle Children's Hospital, Seattle, Washington, United States
Collaborators
No More Kids With Cancer · The Matthew Larson Foundation for Pediatric Brain Tumors · Vyriad, Inc. · Mayo Clinic
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02962167 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University